Successful treatment of generalized granuloma annulare with baricitinib

JAK1/2 pathway‐specific treatment of disseminated granuloma annulare with baricitinib

“…The efficacy of other JAK inhibitors, such as tofacitinib and upadacitinib, in the treatment of GA lesions has also been described (Table 1). 3,[5][6][7][8][9] This case underlines the favourable therapeutic potential of pathway-specific treatment of rare inflammatory diseases. It also emphasizes the importance of considering zoster vaccination prior to initiation of JAK inhibitors, at least in patients older than 50 years and patients without immunity against varicella.…”

Ruxolitinib cream for the treatment of granuloma annulare

“…Recent research has elucidated the involvement of the JAK/signal transducers and activators of transcription (STAT) pathway in the pathogenesis of granuloma annulare, demonstrating constitutive activation of STAT1 and STAT3, 3 in addition to upregulation of JAK2 and JAK3 in lesional skin. 4 Consequently, systemic JAK inhibitors have emerged as promising treatment options for granuloma annulare, with several case reports describing the efficacy of oral tofacitinib, 3 , 5 baricitinib, 6 and upadacitinib. 7 However, systemic immunosuppressive therapy with JAK inhibitors is not without risk, particularly in older patients and those with comorbidities.…”

Baricitinib treatment for refractory skin changes in POEMS syndrome: a case report

“…Vitiligo is an autoimmune skin disease in which melanocytes are reduced in association with the activation of the interferon-γ (IFN-γ) and CXCL-10 signaling pathways ( Frisoli et al, 2020 ). The JAK inhibitor baricitinib, which has been shown to block IFN-γ signaling and contribute to re-pigmentation, has been approved for treatment of patients with vitiligo ( Qi et al, 2021 ; Yan et al, 2022 ). Interestingly, in the present case, hyperpigmentation was treated with baricitinib, which is in contrast to the skin symptoms of vitiligo.…”